Evaluation of photoreceptors health and function in diabetic retinopathy patients using a high-resolution retinal imaging device with controlled light stimulus

使用受控光刺激的高分辨率视网膜成像设备评估糖尿病视网膜病变患者的光感受器健康和功能

• 批准号: 10696696
• 负责人: Mircea Mujat
• 金额: $ 33.11万
• 依托单位: PHYSICAL SCIENCES, INC
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10696696
• 关键词: Area; Biological Markers; Blindness; Blood flow; Brain; Clinical; Collaborations; Color; Communities; Computers; Cone; Development; Diabetes Mellitus; Diabetic Retinopathy; Diameter; Early Diagnosis; Evaluation; Eye diseases; Feedback; Frequencies; Functional Imaging; Functional disorder; Government; Health; Image; Imaging Device; Impairment; Individual; Investigation; Lasers; Learning; Length; Light; Lighting; Location; Measurement; Measures; Metabolic; Methods; Monitor; Ophthalmoscopy; Optical Coherence Tomography; Optics; Patients; Pattern; Performance; Persons; Phase; Photoreceptors; Quality of life; Research; Resolution; Retina; Retinal Cone; Retinal Diseases; Retinal Photoreceptors; Scanning; Signal Transduction; Site; Spottings; Stimulus; System; Techniques; Technology; Testing; Tissues; Validation; Vision; Visual; Volunteer Group; adaptive optics; adaptive optics scanning laser ophthalmoscopy; clinical effect; cohort; design; experience; imager; imaging platform; imaging system; in vivo; instrument; light effects; negative affect; neural; neurovascular coupling; next generation; novel therapeutics; physical science; programs; response; retina blood vessel structure; retinal imaging; tool; transmission process; volunteer

Project Summary/Abstract Physical Sciences Inc (PSI), in collaboration with Joslin Diabetes Center (JDC), proposes to enable objective characterization of the photoreceptor response to light and thus quantification of differences between normal and diseased eyes by adding controlled light stimulus capabilities to an existing high-resolution retinal imaging platform and validating it on a group of volunteers at JDC. We aim to demonstrate the ability to induce and measure vessel diameter changes and to induce and measure reflectivity, transmission, and length changes in cone photoreceptors with the purpose of developing robust biomarkers for diabetic retinopathy (DR). Functional testing of retinal circuitry can provide an unbiased evaluation of one’s vision and enable early detection of retinal diseases and monitoring treatment results. PSI has been developing and offering multiple types of commercial high-resolution retinal imagers for more than fifteen years and is well known as one of the leaders in the field. Based on this experience, we propose to develop and implement light flicker stimulus capabilities in our multichannel adaptive optics retinal imaging (MAORI-X5) platform to objectively test retinal function. MAORI-X5 combines AO-assisted optical coherence tomography (OCT) and scanning laser ophthalmoscopy (SLO) in one instrument and provides in vivo cellular-level resolution imaging of retinal microstuctures. There is no commercially available SLO or OCT system with light flicker capabilities. We propose to fill in this gap and enhance the capabilities of our retinal imaging platform by implementing two types of light flicker: local, cone-level illumination for testing the health and function of photoreceptors, and large area illumination for testing neurovascular coupling. Both types of measurements will reveal the effects of light stimulation with cellular-level resolution. Adding stimulus capabilities to MAORI-X5 enables investigations of neurovascular coupling and functional assessment of retinal photoreceptors on a commercially available platform. We will validate the ability of the technique to measure cellular level effects in Phase I as a proof-of-principle demonstration on a very limited cohort of ten volunteers in collaboration with our clinical partner, Dr. Jennifer Sun, at JDC. A more extensive study will be proposed to quantify these effects and demonstrate clinical usefulness in a subsequent Phase II. PSI prior experience developing advanced ophthalmic imaging systems gives us a competitive advantage in developing the proposed functionality. A successful completion of the Phase I and a subsequent Phase II development will provide clinicians with a high-performance retinal imaging platform for functional imaging. Early adaptors of this technology within the research community will grow our understanding of vision and its disruption by DR, and will enable the investigation of the effects of new drugs and therapies. PSI, the only company worldwide offering commercially AO-SLO-OCT instruments, proposes to develop the next generation of retinal imaging research instruments as a reliable tool to quantify clinically the effects of DR on vision.

项目总结/摘要 物理科学公司（PSI），与乔斯林糖尿病中心（JDC）合作，建议使 光感受器对光响应的客观表征，从而量化 通过将受控光刺激能力添加到现有的高分辨率视网膜 成像平台，并在JDC的一组志愿者身上进行验证。我们的目标是展示诱导 测量血管直径变化，诱导并测量反射率、透射率和长度 视锥光感受器的变化，目的是开发糖尿病视网膜病变的稳健生物标志物 （DR）。视网膜电路的功能测试可以提供对一个人的视力的无偏见的评估， 早期发现视网膜疾病和监测治疗结果。 PSI一直在开发和提供多种类型的商业高分辨率视网膜成像仪， 超过十五年，是该领域的领导者之一。基于这一经验，我们 建议在我们的多通道自适应光学视网膜中开发和实现光闪烁刺激功能 使用MAORI-X5成像平台来客观地测试视网膜功能。MAORI-X5结合了AO辅助光学 相干断层扫描（OCT）和扫描激光检眼镜（SLO）在一个仪器，并提供在 视网膜显微结构的活体细胞水平分辨率成像。没有市售的SLO或 具有光闪烁功能的OCT系统。我们建议填补这一空白，提高我们的能力， 视网膜成像平台，通过实施两种类型的光闪烁：局部，锥水平照明，用于测试 光感受器的健康和功能，以及用于测试神经血管耦合的大面积照明。两 类型的测量将揭示具有细胞级分辨率的光刺激的效果。添加刺激 MAORI-X5的功能使研究神经血管耦合和功能评估成为可能。 视网膜光感受器在市售平台上。我们将验证该技术的能力， 在第一阶段测量细胞水平的影响，作为对非常有限的10人队列的原理验证 志愿者与我们的临床合作伙伴Jennifer Sun博士在JDC合作。一项更广泛的研究将是 建议量化这些影响，并在随后的第二阶段证明临床实用性。 PSI先前开发先进眼科成像系统的经验为我们提供了竞争优势 在开发拟议的功能。成功完成第一阶段和随后的第二阶段 开发将为临床医生提供一个高性能的视网膜成像平台，用于功能成像。 研究界早期采用这项技术的人将增加我们对视觉的理解， 它的破坏由DR，并将使调查的影响，新的药物和疗法。PSI，唯一的 一家在全球范围内提供商用AO-SLO-OCT仪器的公司，建议开发下一代 视网膜成像研究仪器作为一个可靠的工具，量化临床DR对视力的影响。